UK throws veil of secrecy over no-deal Brexit plan

14 August 2019

As the UK begins to make more extensive plans for an abrupt departure from the European Union, the country’s health ministry has confirmed that a number of pharma groups have signed non-disclosure agreements (NDA) concerning the preparations.

A so-called “no-deal Brexit” is widely believed to be more likely following the installment of hardliner Boris Johnson as Prime Minister.

Mr Johnson has said that the UK is “getting ready to come out on October the 31st, come what may,” and an additional £434 million ($523 million) has been made available to facilitate the importation of vital medicines in that eventuality.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK